“Taken together, ATLANTIC’s findings show that “durvalumab is active in heavily pretreated patients, and its degree of activity is related to programmed cell death ligand 1 (PD-L1) expression,” commented invited discussant, Michael Boyer, MBBS, PhD, Chief Clinical Officer and Conjoint Chair of Medical Oncology (Thoracic Oncology), at the Chris O’Brien Lifehouse, Sydney, New South Wales, Australia. The findings are consistent with those among subgroups of similar patients in other trials of immune checkpoint inhibitors.
What the relevance of third- and fourth-line treatment will be in the future will be hard to determine.— Michael Boyer, MBBS, PhD
Tweet this quote
Longer exposure to durvalumab appears to be associated with more adverse events. “This is of relevance when we start thinking about questions about the duration of treatment,” he asserted.
“For me, perhaps the biggest question about these data relates to the emerging data on first-line and second-line use of this class of drugs,” Dr. Boyer concluded. “Clearly, the best performers in this study were the ones with the highest PD-L1 expression. But we know these are the very patients who in the future are likely to be receiving these drugs as part of their first-line treatment. Therefore, what the relevance of third- and fourth-line treatment will be in the future will be hard to determine.” ■
Disclosure: Michael Boyer, MBBS, PhD, has received research support from Genentech/Roche, Pfizer, Eli Lilly, Merck Sharpe and Dohme, AstraZeneca, and Clovis.
The immune checkpoint inhibitor durvalumab (also known as MEDI4736) is active and achieves durable responses in patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) that does not have any epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)...